Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Clinical Relevance of Microbleeds in Acute Stroke Thrombolysis
Neurol 87:1534-1541, Charidimou, A.,et al, 2016
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 43:2904-2909, Whiteley, W.N.,et al, 2012
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients
Storke 38:2738-2744, Fiehler,J.,et al, 2007
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Neurological Emergencies: Acute Stroke
JNNP 68:277-288, Davenport,R. & Dennis,M., 2000